文献速递心脑血管急症消化、代谢与肾脏急症重症综合管理与镇静镇痛

SGLT2抑制剂用于2型糖尿病心血管和肾脏结局的一级和二级预防:心血管结局试验的系统综述与荟萃分析

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
PubMed 文献 · Lancet · 2018-11-10
一句话结论在2型糖尿病患者中,SGLT2抑制剂可降低心衰住院和肾脏病进展风险,且不受动脉粥样硬化性心血管疾病或心衰病史影响;对主要不良心血管事件的获益似乎仅限于已患动脉粥样硬化性心血管疾病者。

该研究为系统综述与荟萃分析,纳入3项随机、安慰剂对照的心血管结局试验,共34 322例2型糖尿病患者(60.2%已患动脉粥样硬化性心血管疾病)。SGLT2抑制剂使主要不良心血管事件风险降低11%(HR 0.89,95%CI 0.83-0.96,p=0.0014),但获益仅见于已患动脉粥样硬化性心血管疾病者(HR 0.86,95%CI 0.80-0.93),未患该病者无获益(HR 1.00,95%CI 0.87-1.16,交互作用p=0.0501)。SGLT2抑制剂使心血管死亡或心衰住院复合风险降低23%(HR 0.77,95%CI 0.71-0.84,p<0.0001),肾脏病进展风险降低45%(HR 0.55,95%CI 0.48-0.64,p<0.0001),这两项获益在有无动脉粥样硬化性心血管疾病及有无心衰病史者中相似。

要点

  • 在2型糖尿病患者中,SGLT2抑制剂使心血管死亡或心衰住院复合风险降低23%(HR 0.77,95%CI 0.71-0.84,p<0.0001),有无动脉粥样硬化性心血管疾病和心衰病史者获益相似。
  • SGLT2抑制剂使肾脏病进展风险降低45%(HR 0.55,95%CI 0.48-0.64,p<0.0001),有无动脉粥样硬化性心血管疾病者获益相似。
  • SGLT2抑制剂使主要不良心血管事件风险降低11%(HR 0.89,95%CI 0.83-0.96,p=0.0014),获益仅见于已患动脉粥样硬化性心血管疾病者(HR 0.86,95%CI 0.80-0.93),未患该病者无获益(HR 1.00,95%CI 0.87-1.16,交互作用p=0.0501)。
  • 基线肾功能越差,SGLT2抑制剂降低心衰住院的幅度越大(交互作用p=0.0073),降低肾脏病进展的幅度越小(交互作用p=0.0258)。

适用人群与场景

  • 纳入3项随机、安慰剂对照心血管结局试验中的2型糖尿病患者,共34 322例,其中60.2%已患动脉粥样硬化性心血管疾病。

研究设计与关键结果

  • 研究类型为系统综述与荟萃分析,检索PubMed和Embase截至2018年9月24日,纳入3项随机、安慰剂对照心血管结局试验,共34 322例2型糖尿病患者(60.2%已患动脉粥样硬化性心血管疾病),累计3342例主要不良心血管事件、2028例心血管死亡或心衰住院事件、766例肾脏复合结局。
  • SGLT2抑制剂使主要不良心血管事件风险降低11%(HR 0.89,95%CI 0.83-0.96,p=0.0014),已患动脉粥样硬化性心血管疾病者HR 0.86(95%CI 0.80-0.93),未患该病者HR 1.00(95%CI 0.87-1.16),交互作用p=0.0501。
  • SGLT2抑制剂使心血管死亡或心衰住院复合风险降低23%(HR 0.77,95%CI 0.71-0.84,p<0.0001),有无动脉粥样硬化性心血管疾病及有无心衰病史者获益相似。
  • SGLT2抑制剂使肾脏病进展风险降低45%(HR 0.55,95%CI 0.48-0.64,p<0.0001),有无动脉粥样硬化性心血管疾病者获益相似。
  • 基线肾功能越差,心衰住院的降低幅度越大(交互作用p=0.0073),肾脏病进展的降低幅度越小(交互作用p=0.0258)。

证据类型、等级与局限

  • 证据类型为系统综述与荟萃分析,纳入3项随机、安慰剂对照心血管结局试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,SGLT2抑制剂对动脉粥样硬化性主要不良心血管事件有中等获益,该获益似乎仅限于已患动脉粥样硬化性心血管疾病者;但对降低心衰住院和延缓肾脏病进展有稳健获益,且不受已患动脉粥样硬化性心血管疾病或心衰病史影响。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The magnitude of effect of sodium-glucose cotransporter-2 inhibitors (SGLT2i) on specific cardiovascular and renal outcomes and whether heterogeneity is based on key baseline characteristics remains undefined.

METHODS: We did a systematic review and meta-analysis of randomised, placebo-controlled, cardiovascular outcome trials of SGLT2i in patients with type 2 diabetes. We searched PubMed and Embase for trials published up to Sept 24, 2018. Data search and extraction were completed with a standardised data form and any discrepancies were resolved by consensus. Efficacy outcomes included major adverse cardiovascular events (myocardial infarction, stroke, or cardiovascular death), the composite of cardiovascular death or hospitalisation for heart failure, and progression of renal disease. Hazard ratios (HRs) with 95% CIs were pooled across trials, and efficacy outcomes were stratified by baseline presence of atherosclerotic cardiovascular disease, heart failure, and degree of renal function.

FINDINGS: We included data from three identified trials and 34 322 patients (60·2% with established atherosclerotic cardiovascular disease), with 3342 major adverse cardiovascular events, 2028 cardiovascular deaths or hospitalisation sfor heart failure events, and 766 renal composite outcomes. SGLT2i reduced major adverse cardiovascular events by 11% (HR 0·89 [95% CI 0·83-0·96], p=0·0014), with benefit only seen in patients with atherosclerotic cardiovascular disease (0·86 [0·80-0·93]) and not in those without (1·00 [0·87-1·16], p for interaction=0·0501). SGLT2i reduced the risk of cardiovascular death or hospitalisation for heart failure by 23% (0·77 [0·71-0·84], p<0·0001), with a similar benefit in patients with and without atherosclerotic cardiovascular disease and with and without a history of heart failure. SGLT2i reduced the risk of progression of renal disease by 45% (0·55 [0·48-0·64], p<0·0001), with a similar benefit in those with and without atherosclerotic cardiovascular disease. The magnitude of benefit of SGLT2i varied with baseline renal function, with greater reductions in hospitalisations for heart failure (p for interaction=0·0073) and lesser reductions in progression of renal disease (p for interaction=0·0258) in patients with more severe kidney disease at baseline.

INTERPRETATION: SGLT2i have moderate benefits on atherosclerotic major adverse cardiovascular events that seem confined to patients with established atherosclerotic cardiovascular disease. However, they have robust benefits on reducing hospitalisation for heart failure and progression of renal disease regardless of existing atherosclerotic cardiovascular disease or a history of heart failure.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2018. PMID: 30424892. doi:10.1016/S0140-6736(18)32590-X

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。